Accuray Stock Forecast, Price & News

Accuray (NASDAQ:ARAY) Frequently Asked Questions

Is Accuray a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Accuray stock.
View analyst ratings for Accuray or view top-rated stocks.

How has Accuray's stock price been impacted by COVID-19?

Accuray's stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARAY shares have increased by 86.8% and is now trading at $4.24.
View which stocks have been most impacted by COVID-19.

When is Accuray's next earnings date?

Accuray is scheduled to release its next quarterly earnings announcement on Wednesday, January 26th 2022.
View our earnings forecast for Accuray.

How can I listen to Accuray's earnings call?

Accuray will be holding an earnings conference call on Wednesday, January 26th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "6302301".

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.01) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.03. The medical equipment provider earned $107.44 million during the quarter. Accuray had a negative net margin of 1.85% and a positive trailing twelve-month return on equity of 3.19%.
View Accuray's earnings history.

What guidance has Accuray issued on next quarter's earnings?

Accuray issued an update on its FY 2022 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $420 million-$427 million, compared to the consensus revenue estimate of $415.82 million.

What price target have analysts set for ARAY?

1 equities research analysts have issued twelve-month price objectives for Accuray's stock. Their forecasts range from $7.50 to $7.50. On average, they anticipate Accuray's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price.
View analysts' price targets for Accuray or view top-rated stocks among Wall Street analysts.

Who are Accuray's key executives?

Accuray's management team includes the following people:

• Joshua H. Levine, Chief Executive Officer & Director (LinkedIn Profile)
• Suzanne C. Winter, President (LinkedIn Profile)
• Michael Hoge, Senior Vice President-Global Operations
• Brandon Wegner Green, Chief Financial Officer
• Jean-Philippe Pignol, Senior VP, Chief Medical & Technology Officer

What is Joshua Levine's approval rating as Accuray's CEO?

78 employees have rated Accuray CEO Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among Accuray's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Accuray's key competitors?

Some companies that are related to Accuray include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of ARAY's competitors.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $4.24.

How much money does Accuray make?

Accuray has a market capitalization of $385.50 million and generates $396.29 million in revenue each year. The medical equipment provider earns $-6.31 million in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does Accuray have?

Accuray employs 932 workers across the globe.

Does Accuray have any subsidiaries?

The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.

When was Accuray founded?

Accuray was founded in 1990.

What is Accuray's official website?

The official website for Accuray is www.accuray.com.

Where are Accuray's headquarters?

Accuray is headquartered at 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at (408) 716-4600, via email at [email protected], or via fax at 408-716-4601.